A new report from the Organization of Pharmaceutical Producers of India (OPPI) and Ernst & Young finds that India remains among the most attractive outsourcing locations for the biopharmaceutical industry. Excluding clinical trials, in 2010, the country is expected to account for 5.7% of the $66 billion pharmaceutical contract research and manufacturing marketing. In a survey of 38 participants at 17 large and medium-sized pharmaceutical firms, India’s cost efficiency was rated as excellent by 67% of respondents, the highest level compared to five other regions (China, Eastern Europe, Puerto Rico, Singapore, Ireland). India also received the highest cumulative ratings for skilled manpower and technical capability. India was ranked third, with a rating of above average given by 67% of respondents, for both response time and project management. However, 67% of respondents rated the country as average for IP protection, while 33% rated it as average for infrastructure. India was rated fourth for regulatory environment, fifth for intellectual property protection, and environmental, health and safety compliance. For infrastructure and tax incentive attractiveness, it was rated sixth.

Source: OPPI